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Application of a Data Analytics Dashboard for a SingleInstitution Laboratory Information System
Brian Harry; Massachusetts General Hospital, Boston
The dynamics of specimen trafficking and testing patterns can inform fundamental laboratory management practices. The objective of this study was to employ a dashboard designed for data analysis and visualization to understand clinical laboratory utilization at a single institution that processes 12 million specimens, admits 48,000 patients, and serves nearly 1.5 million outpatient visits annually. Architecturally, an analytics server queries the laboratory information system (LIS) at 24-hour intervals and populates a database with operational information. The analytical server then supports a customized dashboard offering daily and aggregate operational metrics covering three years of clinical laboratory information. The LIS design is otherwise archetypal and communicates bidirectionally with the electronic medical record system and laboratory instrumentation middleware. The dashboard was queried to reveal important metrics, such as traffic peaks, distribution of sample accession volumes, test turnaround time, and credit/cancel/refusal metrics, with location-level and test-level granularity. A very different pattern in sample accessioning flux was observed for inpatient and outpatient workloads. A single large daily peak for inpatient sample traffic occurs at 6:30 AM, representing approximately 580 samples accessioned between 6:00 and 7:00 AM. Conversely, a bimodal traffic peak for outpatient samples occurs at 2:30 PM and 8:30 PM with approximately 470 samples and 460 samples accessioned during each peak time, respectively. This information allows us to reliably quantify, illustrate, and predict the impact of inpatient phlebotomy collection and outpatient sample delivery workflows on the clinical laboratory. Such data can directly inform staffing decisions, reagent procurement, instrumentation needs, quality control practices, and other laboratory management responsibilities. This model is relevant especially to high volume laboratories with automated accessioning systems. Introduction: Urine antigen (UAg) testing is a rapid, non-invasive, and sensitive method for detecting Histoplasma capsulatum (Histo) and Blastomyces dermatitidis (Blasto) infection. We compared the performance of the Miravista (MV) Diagnostics Histo UAg assay and the Niche Diagnostics (ND) Histo and Blasto UAg assays for detection of endemic fungal infection at a 1,250-bed tertiary care hospital in the Midwestern United States. Methods: A total of 250 banked remnant urine samples from 234 patients submitted to the microbiology laboratory for MV Histo UAg testing were deidentified by an Honest Broker and tested by the ND Histo and Blasto UAg assays. We reviewed the electronic medical record for all included patients to obtain clinicopathologic data relevant to possible fungal infection, including clinical history, antifungal treatment, imaging, histology, culture, and fungal serologic and antigen testing. Patients with diagnoses of histoplasmosis or blastomycosis confirmed by culture or histology were identified. Results: The MV and ND Histo UAg assays were highly concordant (90.5% positive agreement, 99.6% negative agreement, 98.8% overall agreement). A method comparison plot showed positive quantitative bias of the ND assay (slope 1.4). One of 19 concordant positive samples, from a patient with suspected histoplasmosis but a negative diagnostic work-up, was a possible false positive. Three of 228 concordant negative samples were from patients diagnosed with and treated for histoplasmosis: one with culture-and biopsy-proven disease whose antigenuria had resolved with treatment, and two seropositive patients with pulmonary-limited disease and negative UAg at time of diagnosis (possible false negatives). Three samples gave discrepant results: two were from patients diagnosed with and treated for histoplasmosis (of which one was culture-proven), and one was from a patient with culture-proven blastomycosis; Histo UAg concentrations down-trended with treatment in all three cases. The positive results in each of these discrepant cases had UAg concentrations near the lower quantitation limit. While the Histo assays were positive in all three patients with culture-proven blastomycosis, the ND Blasto UAg assay was negative in one case and detectable but below the positive cutoff in the remaining two cases. Histo UAg analysis obtained by both MV and ND assays correlated with the presence of cross-reactivity from the Blasto UAg assay; specifically, specimens whose Blasto UAg results were positive or detectable but below the positive cutoff showed higher mean Histo UAg concentrations than specimens negative for Blasto UAg. Conclusions: The ND and MV Histo UAg assays demonstrate similar analytical performance characteristics for the diagnosis of histoplasmosis, with discrepancies between assays affecting few specimens near the lower limit of detection. Given the paucity of blastomycosis cases in our study, further investigation is required to evaluate the performance of these assays for detection of Blasto. This retrospective study examined the relationship between degree of platelet crossmatch incompatibility (XM) and patient anti-donor HLA antibody mean fluorescence intensity (MFI). A total of 10 patients were selected, each known to have had platelet crossmatch testing (Capture-P, Immucor Inc, Peachtree Corners, GA), recorded degree of crossmatch incompatibility (0 to 4+), and cotemporaneous HLA MFI testing (Luminex Corp, Austin, TX). Tests were performed to evaluate for antibody-mediated platelet refractoriness. MFI was normalized to self-allele beads. If multiple beads were present for a serotype, MFIs were averaged. In total, 155 units were tested by crossmatch; donor HLA type was known for 112, and these were analyzed further. For the four HLA-A/B alleles, there were zero 4-point, five 3-point, 15 2-point, 44 1-point, and 48 0-point matches. XM was 1+ for 26, 2+ for 1, 3+ for 3, 4+ for 3, and 0 for 79 units. Positive control results ranged from 2 to 4+. XM had a positive correlation with MFI against donor HLA (Pearson 0.48 for maximum MFI vs 0.49 for summed MFI). The correlation was not perfect: XM was positive for 9.5% of units with maximum MFI <1,000 and negative for 24% of units with maximum MFI >20,000. A multivariate linear mixed effect model (LM) considered the effect of patient, major ABO incompatibility, crossmatch positive control result, as well as MFI. MFI was included in the LM as either sum or maximum MFI of donor HLA-A/B or as sum or maximum MFI of donor HLA-A and HLA-B alleles separately. Maximum MFI against HLA-A showed the most significant correlation with XM (P = 9.4e-5), compared with maximum MFI against HLA-B (P = .48). Major ABO incompatibility was consistently significant (P ≅ .0002). Maximum MFI against HLA-A correlated slightly better than either the summed MFI or maximum MFI against both HLA-A/B (t value = 4.08 vs 3.37 vs 2.99), but all were significant (P < .03). Similarly, summed MFI against HLA-A was less significant than maximum MFI against HLA-A (t value = 2.79 vs 4.08). Of note, the average number of mismatched alleles was lower for HLA-A vs B (1.4 vs 1.8, P = 5e-6). Additionally, the average maximum MFI was higher for donor HLA-A vs B (5,569 vs 2,939, P = .01), despite a lower average Luminex bead MFI for HLA-A vs B (1,775 vs 2,660, P = .03). In conclusion, maximum MFI to HLA-A and major ABO incompatibility were patient/donor factors that correlated most with XM. The patient population appears preferentially alloimmunized against the HLA-A alleles in the donor population. Additional studies are needed to determine whether this was due to quantitative differences in levels of HLA-A vs HLA-B on donor platelets, allele-specific prior exposure, allele frequency, or differences in epitopes between the proteins used for MFI testing and the common HLA proteins in the platelet donor population. (MM) . While the majority of labs in the US use a method approved by the Food and Drug Administration utilizing polyclonal antibodies to quantitate FLC in serum (The Binding Site, TBS), a method using a cocktail of monoclonal antibodies (Siemens Healthcare) is available for investigational use only. A comparison of the performance of both assays is warranted since patients diagnosed with a MG are followed for life. In this study, 236 serum specimens from 83 unique patients were analyzed for κ and λ FLC in parallel using Siemens and TBS reagent on the BNII nephelometer (Siemens). The cohort included 14 MM, 10 light chain MM (LCMM), 54 amyloidosis (AL). and five MG of undetermined significance (MGUS) patients. 35/236 specimens were obtained at the time of clinical diagnosis (MM [n = 10], LCMM [n = 7] , AL [n = 10], MGUS [n = 8]), while 201 specimens were obtained during monitoring stages. Reference intervals (RIs) for TBS assay were derived in the laboratory and RIs for the Siemens assay were provided by the manufacturer. The k, λ, and κ/λ FLC results were analyzed by Deming regression (TBS as the reference method). The correlation
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